KindlyMD Makes Initial Purchase of 21 Bitcoin as Part of its Treasury Strategy
SALT LAKE CITY--(BUSINESS WIRE)--Kindly MD, Inc. (NASDAQ: NAKA) ('KindlyMD' or the 'Company'), a leading provider of integrated healthcare services, today announced that it has purchased 21 Bitcoin at a weighted average price of $109,027 per Bitcoin for approximately $2.3 million. The Company made this initial purchase of Bitcoin using a portion of the $8,748,370 gross proceeds received from the exercise of some of the Company's outstanding warrants, resulting in the issuance of 1,437,362 shares of common stock of the Company.
The purchase aligns with the Company's vision to adopt a Bitcoin treasury strategy through its proposed merger with Nakamoto Holdings Inc. ('Nakamoto'), a Bitcoin-native holding company.
'KindlyMD chose 21 BTC, which is one millionth of the total supply of bitcoin, as a symbolic first step on our journey to be the leading Bitcoin treasury strategy,' said David Bailey, Founder and CEO of Nakamoto. 'There are many more milestones ahead and we can't wait to continue to execute our roadmap with KindlyMD.'
'There is excitement among our investors going into the 2025 Bitcoin Conference in Las Vegas and today's announcement reinforces our commitment to accumulate Bitcoin and drive long-term value for our shareholders,' said Tim Pickett, CEO of KindlyMD. 'This strategic purchase was possible after significant warrant redemption, which we believe reflects our investor's support of the merger and in our confidence of Bitcoin as a store of value. We look forward to working diligently towards the closing of our merger with Nakamoto to further accelerate our Bitcoin treasury strategy.'
About Nakamoto
Nakamoto is a Bitcoin treasury company building a global portfolio of Bitcoin-native companies. Nakamoto plans to establish the first publicly traded conglomerate of Bitcoin companies by accumulating Bitcoin in its treasury and by leveraging its treasury to acquire and develop an ecosystem of Bitcoin companies across finance, media, advisory and more. The company aims to provide commercial and financial infrastructure for the next generation of capital markets. For more information, please visit nakamoto.com.
About KindlyMD
KindlyMD is a patient-first healthcare and healthcare data company redefining value-based care and patient-centered medical services. KindlyMD leverages data analysis to deliver evidence-based, personalized solutions in order to reduce opioid use, improve health outcomes faster, and provide algorithmic guidance on the use of alternative medicine in healthcare. KindlyMD provides a patient-focused healthcare experience that integrates traditional medical evaluation and management with mental health integration and compliant alternative medicine education and inclusion. It focuses on creating personalized care plans for each individual that get people back to work and life faster, reduce opioid use, and yield high patient satisfaction.
Its specialty outpatient clinical services are reimbursed by Medicare, Medicaid, and commercial insurance contracts as well as offered on a fee-for-service basis. For more information, please visit www.kindlymd.com.
Forward-Looking Statements
All statements, other than statements of historical fact, included in this release that address activities, events or developments that KindlyMD or Nakamoto expects, believes or anticipates will or may occur in the future are forward-looking statements. Words such as 'estimate,' 'project,' 'predict,' 'believe,' 'expect,' 'anticipate,' 'potential,' 'create,' 'intend,' 'could,' 'would,' 'may,' 'plan,' 'will,' 'guidance,' 'look,' 'goal,' 'future,' 'build,' 'focus,' 'continue,' 'strive,' 'allow' or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the proposed merger and related transactions, (collectively, the 'Transactions') the expected closing of the proposed Transactions and the timing thereof and as adjusted descriptions of the post-transaction company and its operations, strategies and plans, integration, debt levels and leverage ratio, capital expenditures, cash flows and anticipated uses thereof, synergies, opportunities and anticipated future performance, including the management team and board of directors of the combined company and expected use of proceeds from the Transactions, and any post-closing transactions contemplated between the combined company and BTC Inc (and/or UTXO, LLC through BTC Inc). Information adjusted for the proposed Transactions should not be considered a forecast of future results. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this release. These include the risk that KindlyMD and Nakamoto businesses (which may include the businesses of BTC Inc and/or UTXO in the future, as applicable) will not be integrated successfully and the risk that KindlyMD or the applicable governing bodies of BTC Inc and/or UTXO may not pursue or approve the terms of an acquisition of BTC Inc and/or UTXO; the risk that cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the possibility that shareholders of KindlyMD may not approve the issuance of new shares of KindlyMD common stock in the Transactions or that shareholders of KindlyMD may not approve the Transactions; the risk that a condition to closing of the Transactions may not be satisfied, that either party may terminate the merger agreement, the subscription agreements of the convertible debt purchase agreement or that the closing of the Transactions might be delayed or not occur at all; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Transactions; the parties do not receive regulatory approval of the Transactions; the occurrence of any other event, change, or other circumstances that could give rise to the termination of the merger agreement relating to the Transactions; the risk that changes in KindlyMD's capital structure and governance could have adverse effects on the market value of its securities; the ability of KindlyMD and Nakamoto to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on KindlyMD and Nakamoto's operating results and business generally; the risk the Transactions could distract management from ongoing business operations or cause KindlyMD and/or Nakamoto to incur substantial costs; the risk that KindlyMD may be unable to reduce expenses or access financing or liquidity; the impact of any related economic downturn; the risk of changes in governmental regulations or enforcement practices; and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond KindlyMD's and Nakamoto's control, including those detailed in KindlyMD's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and such other documents of KindlyMD filed, or to be filed, with the SEC that are or will be available on KindlyMD's website at www.kindlymd.com and on the website of the SEC at www.sec.gov . All forward-looking statements are based on assumptions that KindlyMD and Nakamoto believe to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and neither KindlyMD or Nakamoto undertakes any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Cosmo First commissions new BOPP Film Line at Aurangabad plant
By Aman Shukla Published on June 2, 2025, 10:12 IST Cosmo First Ltd, a global supplier of films for packaging, lamination, labelling, and synthetic paper, has successfully commissioned a new BOPP (Biaxially Oriented Polypropylene) film line at its manufacturing facility in Aurangabad, Maharashtra. The new BOPP line involves a capital expenditure of over ₹400 crore and adds an annual production capacity of 81,200 metric tonnes (MT). With this addition, Cosmo First's total annual BOPP capacity rises by approximately 40%, reaching 2,77,000 MT. This development is part of the company's strategic initiative to scale up production and meet the growing demand for speciality packaging films. Cosmo First has recorded a 10% CAGR in speciality film sales over the past six years. The expanded capacity is expected to support the launch of several new speciality products in the coming quarters. The company stated that the new line features advanced manufacturing technology, aimed at enhancing efficiency and broadening its product offerings in the speciality films and packaging segments. Pankaj Poddar, Group CEO, Cosmo First, stated, 'We expect the line to get filled fast due to current favourable gap in demand and supply in the domestic industry. Further, the new BOPP film line shall be eligible for state govt incentives beside being the most cost-efficient line in India. The Company's focus will be on taking full leverage of the new investments including BOPP line and grow specialty film sales.' Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Axios
an hour ago
- Axios
Exclusive: HHS watchdog finds more than $16B in health savings
The Department of Health and Human Services' watchdog identified more than $16 billion in overpayments, fraudulent billings and possible cost savings in health programs over a half year spanning the Biden and Trump administrations, including more than $3.5 billion to be returned to the government. Why it matters: The semiannual summary, first shared publicly to Axios, comes as the Trump administration says it's prioritizing government efficiency and rooting out waste, fraud and abuse. It reflects growing concern over federal payments to Medicare Advantage plans, along with enforcement actions like McKinsey agreeing to pay $650 million to settle charges that its advice caused Purdue Pharma to submit fraudulent claims stemming from the opioid crisis. The report was sent to Congress late Friday. By the numbers: The HHS Office of Inspector General identified $16.6 billion in real and potential savings from October 2024 through March of this year. The office's investigations identified $3.5 billion in funds due back to the federal government, and its audits found another $451 million that the government will recoup. More than $12 billion in potential cost savings were identified if HHS makes recommended policy changes. The office issued 165 recommendations over the six months. In one example, OIG found that Medicare could have saved $7.7 billion if it lowered payments for swing beds at critical access hospitals so that they match skilled nursing facilities. The change would require action from Congress, and the Centers for Medicare and Medicaid Services said it didn't agree with the recommendation. Nearly 400 civil actions, including settlements, resulted from OIG's work during the period. OIG says its work returned $11 to the federal government for each $1 invested in its office. "Whether it's us, whether it's [the Government Accountability Office], whether it's DOGE, whether it's state auditors, there's always a need for program integrity and oversight," said John Hagg, assistant inspector general in the IG's office of audit services. Zoom in: OIG over the six months covered in the report continued its investigations that raise concerns over improper payments in Medicare Advantage. OIG found that many patient diagnoses reported by privately run Medicare plans were supported only through health risk assessments. That allowed plans to be paid more to care for sicker, more expensive patients without enough supporting documentation, raising questions about their validity, per OIG. OIG recommended that Medicare further restrict plans' abilities to get higher payments based on diagnoses reported only on in-home health risk assessments in order to save an estimated $4.2 billion for Medicare. The office plans to do more work on Medicare Advantage in the near future, Melicia Seay, assistant inspector general in the office of evaluation and inspection, told Axios. "There's a lot of areas in terms of Medicare Advantage that we're exploring, whether it is the payment policy related to the program, the service delivery, quality of care," she said. Catch up quick: President Trump in January abruptly fired several agency inspectors general, including longtime HHS watchdog Christi Grimm. He claimed that"some were not doing their job."
Business Wire
an hour ago
- Business Wire
BRMK Investors Have Opportunity to Lead Broadmark Realty Capital Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Broadmark Realty Capital Inc. ('Broadmark' or 'the Company') (NYSE: BRMK) for violations of the federal securities laws . Investors who owned the Company's securities as of the record date of the May 2023 merger between Broadmark and Ready Capital Corporation (NYSE: RC) (the "Merger"), are encouraged to contact the firm before July 28, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company and Ready Capital made false and misleading statements to the market leading up to the Merger. Ready Capital's originated portfolio included borrowers suffering from financial distress due to high interest rates. Ready Capital's markets of operation had an oversupply of multifamily properties, hampering borrower's ability to raise rents. Ready Capital's Current Expected Credit Loss reserves were materially understated due to catastrophic setbacks in a major development project. Ready Capital's financial projections including dividends per share and book value per share had no basis in fact when the Merger was proposed to Broadmark shareholders. Based on these facts, the Company's public statements were false and materially misleading throughout the Merger period. When the market learned the truth about the merger, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
